NCT00482053 2018-05-14Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCTStanford UniversityPhase 2 Terminated3 enrolled 13 charts
NCT00725062 2017-11-29Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell TransplantMasonic Cancer Center, University of MinnesotaPhase 1 Terminated3 enrolled